Literature DB >> 14618075

Glycoprotein IIb/IIIa receptor inhibitors in acute ST-elevation myocardial infarction: will the combination with thrombolytics become reality?

Uwe Zeymer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14618075     DOI： 10.1023/b:thro.0000003311.73296.10

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  33 in total

1.  A comparison of reteplase with alteplase for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1997-10-16       Impact factor: 91.245

Review 2.  Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.

Authors:  E J Topol
Journal:  Circulation       Date:  1998-01-20       Impact factor: 29.690

3.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.

Authors:  J A de Lemos; E M Antman; C M Gibson; C H McCabe; R P Giugliano; S A Murphy; S A Coulter; K Anderson; J Scherer; M J Frey; R Van Der Wieken; F Van De Werf; E Braunwald
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

4.  Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.

Authors: 
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

5.  Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction.

Authors:  J L Anderson; L A Karagounis; R M Califf
Journal:  Am J Cardiol       Date:  1996-07-01       Impact factor: 2.778

6.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

7.  Comparison of the predictive value of ST segment elevation resolution at 90 and 180 min after start of streptokinase in acute myocardial infarction. A substudy of the hirudin for improvement of thrombolysis (HIT)-4 study.

Authors:  R Schröder; U Zeymer; K Wegscheider; K L Neuhaus
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

8.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Authors: 
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

9.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

10.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.